Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1997 1
1999 1
2001 4
2002 2
2003 1
2004 2
2005 4
2006 6
2007 6
2008 4
2009 5
2010 3
2011 6
2012 5
2013 13
2014 6
2015 7
2016 6
2017 5
2018 12
2019 27
2020 12
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

122 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW. Skljarevski V, et al. JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859. JAMA Neurol. 2018. PMID: 29255900 Free PMC article. Clinical Trial.
OBJECTIVE: To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine prevention. ...MAIN OUTCOMES AND MEASURES: To determine if at least 1 of the 4 doses of galcanezumab tested was superior to …
OBJECTIVE: To assess whether at least 1 dose of galcanezumab was superior to placebo for episodic migraine pr
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Dodick DW, et al. JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853. JAMA. 2018. PMID: 29800211 Free PMC article. Clinical Trial.
IMPORTANCE: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. OBJECTIVE: To assess the efficacy of fremanezumab compared with placebo for prevention
IMPORTANCE: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for tr …
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Stauffer VL, et al. JAMA Neurol. 2018 Sep 1;75(9):1080-1088. doi: 10.1001/jamaneurol.2018.1212. JAMA Neurol. 2018. PMID: 29813147 Free PMC article. Clinical Trial.
OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine with or without aura. DESIGN, SETTING, AND PARTICIPANTS: The EVOLVE-1 (Evaluation of LY2951742 in the Prevention of Episodic
OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the prevention of episodic migraine
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Skljarevski V, et al. Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31. Cephalalgia. 2018. PMID: 29848108 Clinical Trial.
Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention. Methods A global, double-blind, 6-month study of patients with episodic migraine was undertaken with 915 intent-t …
Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine pre
A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. Goadsby PJ, et al. N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848. N Engl J Med. 2017. PMID: 29171821 Free article. Clinical Trial.
A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo group (P<0.001 for each dose vs
A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3% of patients in the 70-mg erenumab gro …
Botulinum toxins for the prevention of migraine in adults.
Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Herd CP, et al. Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2. Cochrane Database Syst Rev. 2018. PMID: 29939406 Free PMC article. Review.
OBJECTIVES: To assess the effects of botulinum toxins versus placebo or active treatment for the prevention or reduction in frequency of chronic or episodic migraine in adults. ...We did not find evidence of a difference in the number of …
OBJECTIVES: To assess the effects of botulinum toxins versus placebo or active treatment for the prevention or reductio …
Acupuncture for the prevention of episodic migraine.
Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR. Linde K, et al. Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD001218. doi: 10.1002/14651858.CD001218.pub3. Cochrane Database Syst Rev. 2016. PMID: 27351677 Free PMC article. Review.
BACKGROUND: Acupuncture is often used for migraine prevention but its effectiveness is still controversial. We present an update of our Cochrane review from 2009. OBJECTIVES: To investigate whether acupuncture is a) more effective than no prophylactic …
BACKGROUND: Acupuncture is often used for migraine prevention but its effectiveness is still controversial. We present …
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R, Mueller M, Ahn AH, Schwartz YC, Grozinski-Wolff M, Janka L, Ashina M. Ferrari MD, et al. Lancet. 2019 Sep 21;394(10203):1030-1040. doi: 10.1016/S0140-6736(19)31946-4. Epub 2019 Aug 16. Lancet. 2019. PMID: 31427046 Clinical Trial.
Participants were randomly assigned (1:1:1) by electronic interactive response technology to subcutaneously administered quarterly fremanezumab (month 1, 675 mg; months 2 and 3: placebo), monthly fremanezumab (month 1: 225 mg in episodic migraine and 675 mg i …
Participants were randomly assigned (1:1:1) by electronic interactive response technology to subcutaneously administered quarterly fremanezu …
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Sun H, et al. Lancet Neurol. 2016 Apr;15(4):382-90. doi: 10.1016/S1474-4422(16)00019-3. Epub 2016 Feb 12. Lancet Neurol. 2016. PMID: 26879279 Clinical Trial.
The mean reductions in monthly migraine days with the 7 mg (-22 [SE 04]) and the 21 mg (-24 [04]) doses were not significantly different from that with placebo. ...INTERPRETATION: These results suggest that AMG 334 70 mg might be a potential therapy fo …
The mean reductions in monthly migraine days with the 7 mg (-22 [SE 04]) and the 21 mg (-24 [04]) doses were not significantly …
Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial.
Hanssen H, Minghetti A, Magon S, Rossmeissl A, Rasenack M, Papadopoulou A, Klenk C, Faude O, Zahner L, Sprenger T, Donath L. Hanssen H, et al. Scand J Med Sci Sports. 2018 Mar;28(3):1103-1112. doi: 10.1111/sms.13023. Epub 2018 Jan 8. Scand J Med Sci Sports. 2018. PMID: 29161767 Clinical Trial.
Our aim was to elucidate whether different aerobic exercise programs at high vs moderate intensities distinctly affect migraine days as primary outcome and retinal vessel parameters as a secondary. In this randomized controlled trial, migrain
Our aim was to elucidate whether different aerobic exercise programs at high vs moderate intensities distinctly affect migr
122 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page